
Page#1
BIOGEN INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per share amounts)
 For the Years Ended December 31,
 2018 2017 2016
Revenues:
Product, net $ 10,886.8 $ 10,354.7 $ 9,817.9
Revenues from anti-CD20 therapeutic programs 1,980.2 1,559.2 1,314.5
Other 585.9 360.0 316.4
Total revenues 13,452.9 12,273.9 11,448.8
Cost and expenses:
Cost of sales, excluding amortization and impairment of
acquired intangible assets 
1,816.3 1,630.0 1,478.7
Research and development 2,597.2 2,253.6 1,973.3
Selling, general and administrative 2,106.3 1,933.9 1,946.6
Amortization and impairment of acquired intangible assets 747.3 814.7 385.6
Collaboration profit (loss) sharing 185.0 112.3 10.2
Acquired in-process research and development 112.5 120.0 —
Restructuring charges 12.0 0.9 33.1
(Gain) loss on fair value remeasurement of contingent
consideration (12.3) 62.7 14.8
TECFIDERA litigation settlement charge — — 454.8
Total cost and expenses 7,564.3 6,928.1 6,297.1
Income from operations 5,888.6 5,345.8 5,151.7
Other income (expense), net 11.0 (217.0) (218.7)
Income before income tax expense and equity in loss of
investee, net of tax 
5,899.6 5,128.8 4,933.0
Income tax expense 1,425.6 2,458.7 1,237.3
Equity in loss of investee, net of tax — — —
Net income 4,474.0 2,670.1 3,695.7
Net income (loss) attributable to noncontrolling interests, net
of tax 43.3 131.0 (7.1)
Net income attributable to Biogen Inc $ 4,430.7 $ 2,539.1 $ 3,702.8
Net income per share:
Basic earnings per share attributable to Biogen Inc $ 21.63 $ 11.94 $ 16.96
Diluted earnings per share attributable to Biogen Inc $ 21.58 $ 11.92 $ 16.93
Weighted-average shares used in calculating:
Basic earnings per share attributable to Biogen Inc 204.9 212.6 218.4
Diluted earnings per share attributable to Biogen Inc 205.3 213.0 218.8
See accompanying notes to these consolidated financial statements.
F- 2
Page#2
BIOGEN INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In millions, except per share amounts)
 As of December 31,
 2018 2017
ASSETS
Current assets:
Cash and cash equivalents $ 1,224.6 $ 1,573.8
Marketable securities 2,313.4 2,115.2
Accounts receivable, net 1,958.5 1,787.0
Due from anti-CD20 therapeutic programs 526.9 532.6
Inventory 929.9 902.7
Other current assets 687.6 962.0
Total current assets 7,640.9 7,873.3
Marketable securities 1,375.9 3,057.3
Property, plant and equipment, net 3,601.2 3,182.4
Intangible assets, net 3,120.0 3,879.6
Goodwill  5,706.4 4,632.5
Deferred tax asset 2,153.9 595.9
Investments and other assets 1,690.6 431.6
Total assets $ 25,288.9 $ 23,652.6
LIABILITIES AND EQUITY
Current liabilities:
Current portion of notes payable $ — $ 3.2
Taxes payable 63.5 68.2
Accounts payable 370.5 395.5
Accrued expenses and other 2,861.2 2,901.3
Total current liabilities 3,295.2 3,368.2
Notes payable 5,936.5 5,935.0
Deferred tax liability 1,636.2 122.6
Other long-term liabilities 1,389.4 1,628.7
Total liabilities 12,257.3 11,054.5
Commitments and contingencies
Equity:
Biogen Inc. shareholders’ equity
Preferred stock, par value $0.001 per share — —
Common stock, par value $0.0005 per share 0.1 0.1
Additional paid-in capital — 97.8
Accumulated other comprehensive loss (240.4) (318.4)
Retained earnings 16,257.0 15,810.4
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively (2,977.1) (2,977.1)
Total Biogen Inc. shareholders’ equity 13,039.6 12,612.8
Noncontrolling interests (8.0) (14.7)
Total equity 13,031.6 12,598.1
Total liabilities and equity $ 25,288.9 $ 23,652.6
See accompanying notes to these consolidated financial statements.
F- 4
Page#3
BIOGEN INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
 
For the Years Ended December 31,
 
2018 2017 2016
Cash flows from operating activities:
Net income $ 4,474.0 $ 2,670.1 $ 3,695.7
Adjustments to reconcile net income to net cash flows from operating
activities:
Depreciation, amortization and impairments 1,016.6 1,081.0 682.7
Acquired in-process research and development 112.5 120.0 —
Share-based compensation 157.5 128.0 154.8
Deferred income taxes 108.3 91.7 (175.0)
Contingent consideration (12.3) 62.7 14.8
Other (69.1) 162.1 89.0
Changes in operating assets and liabilities, net: 
Accounts receivable (205.2) (435.6) (241.4)
Due from anti-CD20 therapeutic programs 5.7 (232.0) 13.9
Inventory (52.1) (94.5) (165.6)
Other assets (119.1) (76.6) 59.1
Accrued expenses and other current liabilities 465.5 (227.4) 622.3
Income tax assets and liabilities 321.7 1,303.9 (232.6)
Other liabilities (16.3) (2.4) 69.5
Net cash flows provided by operating activities 6,187.7 4,551.0 4,587.2
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities 9,173.7 5,565.9 7,378.9
Purchases of marketable securities (7,694.8) (5,355.2) (7,913.2)
Contingent consideration related to Fumapharm AG acquisition (1,500.0) (1,200.0) (1,200.0)
Acquired in-process research and development (112.5) (120.0) —
Purchases of property, plant and equipment (770.6) (867.4) (616.1)
Acquisitions of intangible assets (3.0) (975.4) (111.6)
Purchase of Ionis Pharmaceuticals, Inc. stock (462.9) — —
Investment in Samsung Bioepis (676.6) — —
Other 0.4 (11.0) (22.8)
Net cash flows used in investing activities (2,046.3) (2,963.1) (2,484.8)
Cash flows from financing activities:
Purchases of treasury stock (4,352.6) (1,365.4) (1,000.0)
Payments related to issuance of stock for share-based compensation
(2.1) (5.3) (8.5)
arrangements, net 
Net distribution to noncontrolling interest (36.4) (134.1) —
Repayments of borrowings (3.2) (560.9) (2.7)
Net cash contribution to Bioverativ, Inc — (302.7) —
Contingent consideration payments (58.2) (3.0) (38.6)
Other (19.5) (8.6) (2.8)
Net cash flows used in financing activities (4,472.0) (2,380.0) (1,052.6)
Net increase (decrease) in cash and cash equivalents (330.6) (792.1) 1,049.8
Effect of exchange rate changes on cash and cash equivalents (18.6) 39.4 (31.3)
Cash and cash equivalents, beginning of the year 1,573.8 2,326.5 1,308.0
Cash and cash equivalents, end of the year $ 1,224.6 $ 1,573.8 $ 2,326.5
See accompanying notes to these consolidated financial statements.
F- 5